A single four-week course of rituximab was as effective as 18 months of standard therapy with daily oral cyclophosphamide (CyP) and azathioprine (AZA) for induction and maintenance of remission in patients with severe anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). For either treatment, the number, rate, and severity of adverse events did not differ. ...

Full story from Renal & Urology News: Short-Course Rituximab Produces Long-Term Remissions of ANCA Vasculitis - Renal and Urology News